Key protein behind pulmonary arterial hypertension identified.
London, Oct 26 (ANI): In a groundbreaking discovery, researchers at the University of California, San Diego UCSD is consistently ranked among the top ten public universities for undergraduate education in the United States by U.S. News & World Report. It is a Public Ivy.  For graduate studies, most of UCSD's Ph.D. , have identified a key protein that promotes the development of pulmonary arterial hypertension in humans and mice.
The finding has implications for future drug therapies that may extend the life of patients with pulmonary arterial hypertension and prevent the need for lung transplantation Lung Transplantation Definition
Lung transplantation involves removal of one or both diseased lungs from a patient and the replacement of the lungs with healthy organs from a donor. , currently the only cure for this debilitating de·bil·i·tat·ing
Causing a loss of strength or energy.
Weakening, or reducing the strength of.
Mentioned in: Stress Reduction disease.
In the study, Dr. Patricia Thistlethwaite and colleagues have described the genetic pathway by which vascular smooth muscle Vascular smooth muscle refers to the particular type of smooth muscle found within, and composing the majority of the wall of blood vessels.
Vascular smooth muscle contracts or relaxes to both change the volume of blood vessels and the local blood pressure, a mechanism that cells linked with pulmonary arterial hypertension are switched on to proliferate by a receptor protein receptor protein
An intracellular protein or protein fraction having a high specific affinity for binding agents known to stimulate cellular activity, such as a steroid hormone or cyclic AMP. called Notch-3.
The finding helped researchers to block and reverse the pathway of disease in mice.
"The UCSD UCSD University of California, San Diego (La Jolla, California)
UCSD User Centered System Design
UCSD Urbana-Champaign Sanitary District (Illinois)
UCSD Ultra Cool Sexy Dudes team found that pulmonary hypertension is characterized by overexpression of Notch-3 and that the severity of the disease correlates with the amount of this protein in the lung. We showed that a mouse model lacking this protein does not develop pulmonary hypertension, and in addition, that the disease can be effectively treated with an enzyme called ?-secretase inhibitor, which blocks Notch-3 activation," Nature quoted Thistelthwaite as saying.
In the laboratory, mice with pulmonary arterial hypertension that were treated with the ?-secretase inhibitor showed reversal of the disease.
Forms of this drug are currently in use in Phase 1 trials for the treatment of Alzheimer's disease. Pulmonary arterial hypertension is more common in the human population than is currently realized, and unfortunately, is often fatal," said co-author Dr. Stuart Jamieson.
"Current drugs to treat pulmonary arterial hypertension focus on dilating the arterial vessels but do not address the eventual thickening of the artery walls. Fortunately, by identifying this drug target it seems we are now on the right path to developing an intervention that prevents abnormal cell proliferation," he added.
The study has been published online in Nature Medicine. (ANI)
Copyright 2009 Asian News International The Asian News International (ANI) agency provides multimedia news to China and 50 bureaus in India. It covers virtually all of South Asia since its foundation and presently claims, on its official website, to be the leading South Asia-wide news agency. (ANI) - All Rights Reserved.
Provided by Syndigate.info an Albawaba.com company